US Peptide Synthesis Market (2024-2029)
The US Peptide Synthesis Market was valued at $260.1 Million in 2024 and projected to reach to $420.5 Million by 2029, representing a compound annual growth rate of 10.1%. The US peptide synthesis market is poised for substantial expansion, driven by accelerating biopharmaceutical R&D spending and the rising prevalence of peptide-based therapeutics in clinical pipelines.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Peptide Synthesis Market Trends and Insights
- This expansion reflects the US's leadership in biopharmaceutical innovation and increasing demand for custom peptide manufacturing across therapeutic and research applications.
- The US market benefits from advanced infrastructure, significant R&D investment, and a strong presence of contract research organizations (CROs) specializing in peptide production. Driving this growth, the US peptide synthesis sector is responding to rising demand for peptide-based therapeutics, personalized medicine, and immunotherapy development.
- Between 2024 and 2029, the US market will be shaped by technological advancements in solid-phase and liquid-phase synthesis, regulatory support for novel peptide drugs, and expanding applications in oncology and metabolic disorders.
- The US continues to attract global pharmaceutical and biotech companies seeking reliable peptide manufacturing partners. The competitive landscape in the US remains dynamic, with established contract manufacturers and emerging biotech firms competing for market share.
- The US peptide synthesis market's 10.1% CAGR outpaces global growth, underscoring the country's strategic importance in the global peptide supply chain and its role as a hub for cutting-edge peptide-based drug development..
Key Market Statistics
- CAGR (2024-2029) 10.1% CAGR
- Market Size, 2024 ~USD 260.1 Million
- Forecast, 2029 ~USD 420.5 Million
- Country US
US Peptide Synthesis Market Overview
Market Valuation :
The US peptide synthesis market is valued at $260.1 million in 2024, with strong growth trajectory driven by biopharmaceutical innovation and therapeutic development across the country.
Robust CAGR Growth :
The US market is expanding at a 10.1% CAGR from 2024 to 2029, outpacing the global growth rate of 8.7%, reflecting the region's competitive advantage in peptide manufacturing.
Advanced Infrastructure :
The US benefits from world-class research facilities, established biopharmaceutical hubs, and significant capital investment in peptide synthesis technologies and custom manufacturing capabilities.
Diverse Application Demand :
Growing demand for custom peptides spans therapeutic development, clinical research, diagnostics, and academic institutions, creating multiple revenue streams across the US market.
US Peptide Synthesis Market Dynamics
- The country's leadership in drug development, coupled with increasing outsourcing of peptide manufacturing to specialized providers, will fuel market growth through 2029.
- Technological advancements in automated synthesis platforms and growing adoption of peptides in personalized medicine further strengthen market dynamics.
- The US market's 10.1% CAGR reflects strong investor confidence and sustained demand from pharmaceutical companies, biotech firms, and research institutions seeking high-quality custom peptide solutions..
Market Ecosystem
PEPTIDE SYNTHESIS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Has worked with GenScript Biotech Corporation (China) to generate thousands of peptides used to study T-cell receptor recognition and identify novel targets for solid-tumor therapeutics. | Enabled large-scale generation of diverse peptide libraries required for target discovery, supporting identification of tumor-specific targets and development of potentially safer and more effective T-cell receptor therapies. |
 |
Uses Biotage AB (Sweden) peptide synthesis and downstream processing technologies, including Syro automated peptide synthesizers, Initiator+ microwave systems, Isolera purification systems, and V-10 evaporation systems, within its peptide drug-discovery workflows. | Parallel synthesis increased peptide throughput, while heated synthesis shortened coupling times for certain reactions from around one hour to about 10 minutes. The integrated workflow also supports difficult sequences, faster purification, and expansion of peptide discovery programs. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- The US peptide synthesis market is valued at $260.1 million in 2024 and will reach $420.5 million by 2029, growing at a 10.1% CAGR.
- The US market is driven by increasing demand for peptide-based therapeutics, personalized medicine, and immunotherapy applications across multiple disease areas.
- Advanced manufacturing technologies and strong regulatory support position the US as a global leader in peptide synthesis innovation and contract manufacturing.
- The US peptide synthesis market's growth rate exceeds global averages, reflecting the country's competitive advantages in biopharmaceutical infrastructure and R&D capabilities.
Peptide Synthesis Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | CANCER (Indication) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 8.7% from 2024 to 2029 |
| Largest Segment | CHEMICAL METHODS (Technique) |
| Market Size Base Year (Billions) | ~USD 0.93 (2024) |
| Revenue Forecast (Billions) | ~USD 1.41 (2029) |
| Segments Covered | Offering, Type, Technique, Application, Indication |
US Peptide Synthesis Market Report Segmentation
5 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Amino Acids
- Automated Peptide Synthesizers
- Chromatography Systems
- Cleavage Reagents
- Consumables
- Coupling Reagents
- Deprotection Reagents
- Dyes & Fluorescent Labeling Reagents
- Enzymatic Synthesis
- Instruments
- Liquid-Phase Peptide Synthesis
- Lyophilizers
- Manual Peptide Synthesizers
- Other Chemical Methods
- Other Consumables
- Other Instruments
- Other Reagents
- Peptide Synthesizers
- Reagents
- Recombinant Dna Technology
- Resins
- Solid-Phase Peptide Synthesis
By Technique
- Biological Methods
- Chemical Methods
By Application
- Diagnostic Applications
- Discovery & Development Applications
- Therapeutic Applications
By Indication
- Autoimmune Diseases
- Cancer
- Diabetes
- Obesity
- Other Diseases
Target Audience
- Pharmaceutical Companies : US-based and international pharma firms need market intelligence to evaluate peptide synthesis outsourcing opportunities, identify reliable domestic suppliers, and plan peptide-based drug development investments.
- Contract Manufacturing Organizations (CMOs) : CMOs require detailed US market data to assess growth opportunities, benchmark capacity expansion plans, and understand demand trends from biopharmaceutical clients across therapeutic areas.
- Biotech & Research Institutions : Academic centers and biotech startups need US market insights to secure funding, validate business models for peptide synthesis services, and understand competitive positioning in the American market.
- Investors & Private Equity : Investment firms evaluating peptide synthesis companies require US-specific market data, growth projections, and regional dynamics to assess portfolio opportunities and valuation benchmarks.
- Equipment & Technology Providers : Suppliers of peptide synthesis platforms and automation technologies need US market forecasts to identify customer segments, plan product development, and target sales efforts in the growing American market.
Key Companies in the US Peptide Synthesis Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government nuclear, remediation, security, logistics, O&M), |
| MERCK KGAA | Germany | Public Company | Life Science (tools, consumables, CDMO, bioprocessing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, gases, equipment), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| GENSCRIPT | Hong Kong | Public Company | Life Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products, |
| BACHEM | Switzerland | Public Company | Peptide NCE APIs (clinical and commercial),Generic peptide APIs,Oligonucleotide NCE APIs, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery chemistry,Discovery biology and DMPK,Development services (chemical, formulation, analytical, clinical), |
| BIOTAGE | Sweden | Private Company | Flash chromatography systems and consumables,Sample preparation and SPE workflows,Biomolecule purification (antibody, plasmid, AAV, tagged proteins), |
| CEM CORPORATION | Mexico | Public Company | Gray ordinary Portland cement,White and blended cement, masonry products,Ready-mix concrete (standard and specialty), |
FLUOR CORPORATION
Fluor Corporation is a publicly traded engineering and construction company founded in 1912 and headquartered in the United States. With approximately 23,000 employees, the company provides design, engineering, procurement, and construction services across multiple industries.
MERCK KGAA
Merck KGaA is a German publicly traded pharmaceutical, chemical, and life sciences company with roots dating back to 1668. The company employs approximately 59,000 people and operates globally across healthcare, life sciences, and performance materials sectors.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a publicly traded American company founded in 1999 that specializes in life sciences, diagnostics, and applied chemical markets. With approximately 18,000 employees, Agilent provides instruments, software, services, and consumables for laboratory and clinical settings.
GENSCRIPT
GenScript is a Hong Kong-based publicly traded biotechnology company founded in 2002 with approximately 6,165 employees. The company provides gene synthesis, protein production, and drug discovery services to support research and development globally.
BACHEM
Bachem is a Swiss publicly traded company founded in 1971 with approximately 2,725 employees specializing in the production of biochemical compounds. The company serves the pharmaceutical, biotechnology, and diagnostics industries with custom synthesis and manufacturing services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is an Indian publicly traded company founded in 1993 with approximately 6,692 employees providing integrated drug discovery and development services. The company offers preclinical, clinical, and manufacturing services to pharmaceutical and biotechnology clients worldwide.
BIOTAGE
Biotage is a Swedish private company founded in 1969 with approximately 622 employees specializing in laboratory chemistry and sample preparation solutions. The company develops and manufactures instruments and consumables for pharmaceutical, chemical, and environmental analysis.
CEM CORPORATION
CEM Corporation is a publicly traded company founded in 1906 and headquartered in Mexico with approximately 38,495 employees. The company operates across multiple industrial and commercial sectors providing manufacturing and related services.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise US market valuation ($260.1M in 2024) and verified 10.1% CAGR projections through 2029 to support investment decisions and strategic planning in the American peptide synthesis sector.
- Competitive Positioning Intelligence : Understand how the US market outperforms global growth rates (10.1% vs 8.7%), enabling companies to benchmark performance and identify competitive advantages within the domestic landscape.
- Regional Market Dynamics : Access US-specific insights on infrastructure, R&D investment patterns, and manufacturing capabilities that differentiate the American market from other regions and drive growth opportunities.
- Forecast-Driven Strategy : Leverage detailed projections showing market expansion to $420.5M by 2029 to guide capacity planning, resource allocation, and market entry strategies for the next five years.
- Stakeholder-Specific Insights : Gain tailored analysis relevant to pharmaceutical companies, contract manufacturers, investors, and research institutions operating within the US peptide synthesis ecosystem.
Frequently asked questions
What is the current size of the US peptide synthesis market?
The US peptide synthesis market was valued at $260.1 million in 2024 and is projected to grow to $420.5 million by 2029.
What is the expected growth rate for the US peptide synthesis market?
The US peptide synthesis market is expected to grow at a compound annual growth rate (CAGR) of 10.1% from 2024 to 2029.
What are the primary drivers of growth in the US peptide synthesis market?
Key drivers include rising demand for peptide-based therapeutics, advances in synthesis technologies, expansion of immunotherapy applications, and strong regulatory support for novel peptide drugs in the US.
Which therapeutic areas are fueling US peptide synthesis market expansion?
Oncology, metabolic disorders, immunotherapy, and personalized medicine are among the primary therapeutic areas driving demand for peptide synthesis in the US market.
How does the US peptide synthesis market compare to global growth?
The US market's 10.1% CAGR outpaces the global peptide synthesis market CAGR of 8.7%, reflecting the US's leadership position and competitive advantages in biopharmaceutical innovation.
RESEARCH METHODOLOGY
This research study relied extensively on secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global peptide synthesis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the peptide synthesis market. The secondary sources used for this study include US Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), European Directorate for the Quality of Medicines & HealthCare (EDQM), Japan Pharmaceuticals and Medical Devices Agency (PMDA), World Health Organization (WHO), US Pharmacopeia (USP), ClinicalTrials.gov, Journal of Peptide Science, International Journal of Peptide Research and Therapeutics, Peptide Science, American Peptide Society (APS), European Peptide Society (EPS), Chemical & Engineering News (C&EN), Genetic Engineering & Biotechnology News (GEN), and BioPharm International; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations, among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess the market's future prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the peptide synthesis market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following.
Peptide Synthesis Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Peptide synthesis is the process of producing peptides through the controlled assembly of amino acids into specific sequences using chemical, biological, or hybrid manufacturing approaches.
The peptide synthesis market comprises the global commercial market for products and services used to chemically or biologically synthesize, modify, purify, and characterize peptides for research, drug discovery and development, diagnostics, therapeutics, and other life science applications. The market includes peptide synthesis instruments and systems, synthesis reagents and building blocks, purification and analytical instruments, synthesis-related consumables, and custom peptide synthesis services. Services covered include custom peptide synthesis, peptide engineering and modification, peptide labeling and conjugation, peptide purification, and peptide-specific analytical and characterization services provided by CROs, CDMOs and specialized peptide service providers.
Key Stakeholders
- Peptide synthesis instrument manufacturers
- Peptide synthesis reagent and consumable suppliers
- Custom peptide synthesis and specialized peptide service providers
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs) & contract development and manufacturing organizations (CDMOs)
- Academic & research institutes
- Medical device companies
- Clinical & diagnostic laboratories
- Market research & consulting firms
- Regulatory bodies
Report Objectives
- To define, describe, and forecast the global peptide synthesis market based on offering, product type, technique, service type, application, product end user, service end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall peptide synthesis market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product & service portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product & service launches, expansions, and R&D activities in the peptide synthesis market
- To analyze and provide funding & investment activities, brand/product/service comparative analysis, and vendor valuation & financial metrics of the peptide synthesis market
Available customizations:
Based on the given market data, MarketsandMarkets offers customization to meet the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product portfolios of the top four companies.
Company Information
-
Detailed analysis and profiling of additional market players (up to five).
Geographical Analysis
- A further breakdown of the Rest of Europe peptide synthesis market, by country
- A further breakdown of the Rest of Asia Pacific peptide synthesis market, by country
- A further breakdown of the Rest of Latin America peptide synthesis market, by country
Get the Full Peptide Synthesis Market Report
Full forecast, segment splits, and company analysis for all Peptide Synthesis Market.
- Canada Peptide Synthesis Market
- Germany Peptide Synthesis Market
- UK Peptide Synthesis Market
- France Peptide Synthesis Market
- Italy Peptide Synthesis Market
- Spain Peptide Synthesis Market
- China Peptide Synthesis Market
- Japan Peptide Synthesis Market
- India Peptide Synthesis Market
- South Korea Peptide Synthesis Market
- Australia Peptide Synthesis Market
- Brazil Peptide Synthesis Market
- Mexico Peptide Synthesis Market
- Saudi Arabia Peptide Synthesis Market
- UAE Peptide Synthesis Market
- Rest Of Europe Peptide Synthesis Market
- Rest Of Asia Pacific Peptide Synthesis Market
- Rest Of Latin America Peptide Synthesis Market
- Rest Of GCC Countries Peptide Synthesis Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
